CA2790823A1 - Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy - Google Patents

Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy Download PDF

Info

Publication number
CA2790823A1
CA2790823A1 CA2790823A CA2790823A CA2790823A1 CA 2790823 A1 CA2790823 A1 CA 2790823A1 CA 2790823 A CA2790823 A CA 2790823A CA 2790823 A CA2790823 A CA 2790823A CA 2790823 A1 CA2790823 A1 CA 2790823A1
Authority
CA
Canada
Prior art keywords
arg
muscle
lys
peptide
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2790823A
Other languages
English (en)
French (fr)
Inventor
Hazel H. Szeto
Scott Kline Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
University of Florida Research Foundation Inc
Original Assignee
Cornell University
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University, University of Florida Research Foundation Inc filed Critical Cornell University
Publication of CA2790823A1 publication Critical patent/CA2790823A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2790823A 2010-02-26 2011-02-25 Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy Abandoned CA2790823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30850810P 2010-02-26 2010-02-26
US61/308,508 2010-02-26
PCT/US2011/026339 WO2011106717A1 (en) 2010-02-26 2011-02-25 Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy

Publications (1)

Publication Number Publication Date
CA2790823A1 true CA2790823A1 (en) 2011-09-01

Family

ID=44507242

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2790823A Abandoned CA2790823A1 (en) 2010-02-26 2011-02-25 Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy

Country Status (6)

Country Link
US (6) US20130040901A1 (https=)
EP (4) EP3332795A1 (https=)
JP (4) JP2013521231A (https=)
CN (2) CN102834105A (https=)
CA (1) CA2790823A1 (https=)
WO (1) WO2011106717A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2470191T3 (pl) 2009-08-24 2014-09-30 Stealth Peptides Int Inc Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
EP3375449A1 (en) * 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP3009141A1 (en) * 2011-12-09 2016-04-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6317324B2 (ja) * 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
HK1210953A1 (en) * 2012-08-02 2016-05-13 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
CN110339339A (zh) * 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2014210056A1 (en) * 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
WO2016029027A2 (en) * 2014-08-21 2016-02-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
WO2016144968A1 (en) * 2015-03-09 2016-09-15 University Of Washington Relaxin therapy for disorders of the diaphragm
CA3010599C (en) * 2016-01-06 2025-05-20 Stealth Biotherapeutics Inc. METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
WO2017201433A1 (en) * 2016-05-19 2017-11-23 Stealth Biotherapeutics Corp Compositions and methods for the prevention and treatment of mitochondrial myopathies
US10398732B2 (en) 2016-10-13 2019-09-03 Marshall University Research Corporation Compositions and methods for treating striated muscle injury, treating striated muscle atrophy and/or for promoting striated muscle growth
KR101986882B1 (ko) * 2017-01-06 2019-06-07 연세대학교 산학협력단 오시멘, 유게놀 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물
JP2019099488A (ja) * 2017-11-30 2019-06-24 小林製薬株式会社 ペプチド及びその利用
CA3191819A1 (en) * 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria
CN115400201A (zh) * 2021-05-26 2022-11-29 四川大学华西医院 Ss-31在制备预防和/或治疗香烟诱导的气道炎症及慢性阻塞性肺疾病的药物中的用途
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN114870000B (zh) * 2022-03-21 2025-10-28 中国人民解放军空军军医大学 用于线粒体靶向治疗的两亲性前药及其纳米颗粒的制备方法和应用
CN116350745A (zh) * 2023-05-05 2023-06-30 完美（广东）日用品有限公司 小分子活性寡肽在制备改善骨骼肌功能障碍和/或增强骨骼肌收缩功能产品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
CA2851972C (en) * 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3563862B1 (en) * 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
AU2011207432A1 (en) * 2010-01-25 2012-08-02 Cornell University Aromatic-cationic peptides and uses of same

Also Published As

Publication number Publication date
US20130040901A1 (en) 2013-02-14
US20230076067A1 (en) 2023-03-09
CN104922653A (zh) 2015-09-23
JP2013521231A (ja) 2013-06-10
EP2538958A4 (en) 2013-08-28
EP3167896A1 (en) 2017-05-17
US20160058826A1 (en) 2016-03-03
EP3511012A1 (en) 2019-07-17
JP2019069985A (ja) 2019-05-09
JP2016164194A (ja) 2016-09-08
US20200282003A1 (en) 2020-09-10
EP2538958A1 (en) 2013-01-02
US20170143784A1 (en) 2017-05-25
US20180311301A1 (en) 2018-11-01
EP3332795A1 (en) 2018-06-13
JP2017226699A (ja) 2017-12-28
CN102834105A (zh) 2012-12-19
WO2011106717A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
US20230076067A1 (en) Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
US12102659B2 (en) Methods for the prevention or treatment of heart failure
US20190336566A1 (en) Methods for the prevention or treatment of vessel occlusion injury
EP3251686A1 (en) Methods for preventing or treating metabolic syndrome
US11672841B2 (en) Methods for treating heart disease in a subject with Friedreich's ataxia by an aromatic-cationic peptide
WO2016004441A1 (en) Methods for the prevention or treatment of acute myocardial infarction injury
HK1233532A1 (en) Methods for the prevention or treatment of cardiac fibrosis
HK1233532B (en) Methods for the prevention or treatment of cardiac fibrosis
HK1242194A1 (en) Methods for preventing or treating metabolic syndrome
HK1224948A1 (en) Methods for preventing or treating metabolic syndrome

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160217

FZDE Discontinued

Effective date: 20190516